UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1897) 1897
science & technology (1591) 1591
life sciences & biomedicine (1577) 1577
male (1528) 1528
female (1269) 1269
2-pyridinylmethylsulfinylbenzimidazoles (1195) 1195
omeprazole - analogs & derivatives (1072) 1072
adult (1067) 1067
middle aged (1023) 1023
lansoprazole (988) 988
gastroenterology & hepatology (812) 812
proton pump inhibitors (753) 753
pharmacology & pharmacy (701) 701
aged (653) 653
anti-ulcer agents - administration & dosage (629) 629
omeprazole - administration & dosage (592) 592
helicobacter infections - drug therapy (559) 559
treatment outcome (555) 555
anti-ulcer agents - therapeutic use (506) 506
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (498) 498
rabeprazole (454) 454
drug therapy, combination (449) 449
helicobacter pylori (441) 441
omeprazole - therapeutic use (413) 413
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (350) 350
gastroesophageal reflux - drug therapy (335) 335
benzimidazoles - administration & dosage (319) 319
pantoprazole (316) 316
double-blind method (313) 313
amoxicillin - administration & dosage (309) 309
drug administration schedule (302) 302
clarithromycin - administration & dosage (286) 286
anti-bacterial agents - administration & dosage (268) 268
prospective studies (260) 260
dose-response relationship, drug (258) 258
adolescent (253) 253
proton pump inhibitors - administration & dosage (253) 253
administration, oral (251) 251
anti-ulcer agents - pharmacology (236) 236
helicobacter pylori - drug effects (232) 232
cross-over studies (231) 231
animals (230) 230
time factors (222) 222
omeprazole - pharmacology (221) 221
abridged index medicus (220) 220
benzimidazoles - therapeutic use (220) 220
anti-ulcer agents - adverse effects (203) 203
2-pyridinylmethylsulfinylbenzimidazoles - adverse effects (193) 193
aged, 80 and over (191) 191
sulfoxides - administration & dosage (191) 191
hydrogen-ion concentration (188) 188
enzyme inhibitors - administration & dosage (181) 181
anti-bacterial agents - therapeutic use (179) 179
cytochrome p-450 cyp2c19 (176) 176
proton pump inhibitors - therapeutic use (176) 176
omeprazole - adverse effects (175) 175
medicine & public health (172) 172
proton pump inhibitor (171) 171
benzimidazoles - pharmacology (158) 158
amoxicillin - therapeutic use (156) 156
clarithromycin - therapeutic use (154) 154
omeprazole - pharmacokinetics (154) 154
2-pyridinylmethylsulfinylbenzimidazoles - pharmacology (147) 147
rats (146) 146
young adult (145) 145
drug interactions (143) 143
gastroesophageal reflux (142) 142
2-pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics (140) 140
peptic ulcer - drug therapy (140) 140
anti-ulcer agents - pharmacokinetics (136) 136
duodenal ulcer - drug therapy (132) 132
enzyme inhibitors - therapeutic use (132) 132
sulfoxides - therapeutic use (132) 132
gastric acidity determination (131) 131
metronidazole - administration & dosage (131) 131
aryl hydrocarbon hydroxylases - genetics (130) 130
follow-up studies (130) 130
gastroenterology (126) 126
omeprazole (125) 125
area under curve (124) 124
genotype (121) 121
general & internal medicine (119) 119
proton pump inhibitors - adverse effects (119) 119
helicobacter infections - complications (118) 118
benzimidazoles - adverse effects (117) 117
helicobacter infections - microbiology (117) 117
gastric acid - secretion (114) 114
esophagitis, peptic - drug therapy (113) 113
stomach ulcer - drug therapy (111) 111
pharmacokinetics (110) 110
gastric acid - metabolism (109) 109
helicobacter pylori - isolation & purification (108) 108
oncology (108) 108
medicine, general & internal (106) 106
care and treatment (102) 102
gastric mucosa - drug effects (100) 100
internal medicine (98) 98
hepatology (95) 95
enzyme inhibitors - pharmacology (94) 94
sulfoxides - pharmacology (93) 93
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1976) 1976
Japanese (109) 109
German (36) 36
Russian (33) 33
Spanish (19) 19
Chinese (15) 15
Portuguese (11) 11
French (8) 8
Korean (5) 5
Czech (2) 2
Hungarian (2) 2
Norwegian (2) 2
Croatian (1) 1
Danish (1) 1
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
European journal of clinical pharmacology, ISSN 0031-6970, 9/2018, Volume 74, Issue 9, pp. 1149 - 1157
Ilaprazole, the latest proton pump inhibitor, can be used with clarithromycin and amoxicillin as a triple therapy regimen for eradicating Helicobacter pylori.... 
Clarithromycin | Biomedicine | Amoxicillin | Drug interaction | Ilaprazole | Pharmacology/Toxicology | Pharmacokinetics | Proton pump inhibitor | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Anti-Bacterial Agents - blood | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Healthy Volunteers | Clarithromycin - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - pharmacokinetics | Patient Safety | Clarithromycin - administration & dosage | Adult | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Proton Pump Inhibitors - blood | Drug Therapy, Combination | Republic of Korea | Proton Pump Inhibitors - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics | Risk Assessment | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Amoxicillin - blood | Amoxicillin - pharmacokinetics | Cross-Over Studies | Proton Pump Inhibitors - pharmacokinetics | Anti-Bacterial Agents - pharmacokinetics | Amoxicillin - adverse effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | 2-Pyridinylmethylsulfinylbenzimidazoles - blood | Helicobacter Infections - microbiology | Complications and side effects | Dosage and administration | Safety and security measures | Drug interactions | Confidence intervals | Therapy | Randomization | Statistical analysis | Pharmacology | Safety | Index Medicus | Pharmacokinetics and Disposition
Journal Article
Journal Article
Journal Article
Journal Article
Cardiovascular therapeutics, ISSN 1755-5914, 04/2015, Volume 33, Issue 2, pp. 27 - 34
... in patients taking APT. The risk of bleeding seems to be dose dependent for aspirin. Combined administration of APT with proton pump inhibitors (PPI) decreased... 
Ventricular arrhythmias | Proton pump inhibitors | Pantoprazole | Ischemia/reperfusion | Cardiac & Cardiovascular Systems | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Proton Pump Inhibitors - pharmacology | Arrhythmias, Cardiac - chemically induced | Rats, Wistar | Myocardial Reperfusion Injury - complications | Anti-Arrhythmia Agents - pharmacology | Tachycardia, Ventricular - chemically induced | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Arrhythmias, Cardiac - physiopathology | Time Factors | Ventricular Premature Complexes - prevention & control | Ventricular Premature Complexes - physiopathology | Myocardial Ischemia - physiopathology | Ventricular Fibrillation - physiopathology | Myocardial Reperfusion Injury - blood | Disease Models, Animal | Ventricular Fibrillation - prevention & control | Arrhythmias, Cardiac - prevention & control | Nitric Oxide - blood | Anti-Arrhythmia Agents - toxicity | Myocardial Ischemia - blood | Heart Conduction System - drug effects | Tachycardia, Ventricular - prevention & control | Proton Pump Inhibitors - toxicity | Myocardial Reperfusion Injury - physiopathology | Ventricular Premature Complexes - chemically induced | 2-Pyridinylmethylsulfinylbenzimidazoles - toxicity | Tachycardia, Ventricular - physiopathology | Animals | Heart Conduction System - physiopathology | L-Lactate Dehydrogenase - blood | Myocardial Ischemia - complications | Ventricular Fibrillation - chemically induced | Hyperkalemia - chemically induced | Arrhythmias, Cardiac - blood | Arrhythmia | Ischemia | Nitric oxide | Mortality | Anti-arrhythmia drugs | Index Medicus
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 01/2012, Volume 73, Issue 1, pp. 140 - 143
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Triple therapy using a proton pump inhibitor with two antibiotics is the standard treatment for H. pylori infection.... 
proton pump inhibitors/administration and dosage | drug therapy | Helicobacter pylori/drug therapy | amoxicillin/administration and dosage | combination | Amoxicillin/administration and dosage | Drug therapy | Combination | Proton pump inhibitors/administration and dosage | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Enzyme Inhibitors - adverse effects | Drug Administration Schedule | Proton Pump Inhibitors | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Treatment Outcome | Enzyme Inhibitors - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Adult | Amoxicillin - adverse effects | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Lansoprazole | Republic of Korea | Medical colleges | Drug resistance in microorganisms | Care and treatment | Helicobacter pylori | Analysis | Amoxicillin | Peptic ulcer | Helicobacter infections | Proton pump inhibitors | Drug therapy, Combination | Health aspects | Infection | Protons | Clarithromycin | Side effects | Antibiotics | peptic ulcers | Antibiotic resistance | Index Medicus | amoxicillin | proton pump inhibitors | administration and dosage | Short Report
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9862, pp. 205 - 213
Journal Article
Clinical pharmacology and therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
...). Relative to levels after administration of clopidogrel alone in studies 1,2,3, and 4, coadministration of PPI decreased the AUC0... 
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article